Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: The role of neutral endopeptidase

Nephron - Physiology

Volumn 103, Issue 3, 2006, Pages

  Maric, Christine ^a   Zheng, Wei ^a   Walther, Thomas ^b,c  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Angiotensin II; Cell proliferation; Extracellular matrix synthesis; Neutral endopeptidase; Renomedullary interstitial cells

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; CYSTEINE; DNA; ENKEPHALINASE INHIBITOR; GLUCOSE; MEMBRANE METALLOENDOPEPTIDASE; METHIONINE; THYMIDINE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DNA SYNTHESIS; EXTRACELLULAR MATRIX; FEMALE; HYPERGLYCEMIA; KIDNEY FIBROSIS; KIDNEY MEDULLA; LIGAND BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RENAL PROTECTION; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; DRUG INTERACTION; METABOLISM; MOUSE MUTANT; PHYSIOLOGY;

ANGIOTENSIN II; ANIMALS; ATRIAL NATRIURETIC FACTOR; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXTRACELLULAR MATRIX; FEMALE; GLUCOSE; KIDNEY MEDULLA; MICE; MICE, KNOCKOUT; NEPRILYSIN;

EID: 33745432566     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000092457     Document Type: Article

References (34)

1. Fioretto P, Solini A: Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005;16(suppl 1):S18-S21.
2. Wolf G, Ritz E: Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. Kidney Int 2005;67:799-812.
3. Kubota E, Dean RG, Hubner RA, Casley DJ, Johnston CI, Burrell LM: Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. Clin Sci (Lond) 2003;105:339-345.
4. Ryndin I, Gulmi FA, Chou SY, Mooppan UM, Kim H: Renal responses to atrial natriuretic peptide are preserved in bilateral ureteral obstruction and augmented by neutral endopeptidase inhibition. J Urol 2005;173:651-656.
5. Ogihara T, Rakugi H, Masuo K, Yu H, Nagano M, Mikami H: Antihypertensive effects of the neutral endopeptidase inhibitor SCH 42495 in essential hypertension. Am J Hypertens 1994;7:943-947.
6. Bevan EG, Connell JM, Doyle J, et al: Candoxatril, a neutral endopeptidase inhibitor: Efficacy and tolerability in essential hypertension. J Hypertens 1992;10:607-613.
7. Kubota E, Dean RG, Balding LC, Burrell LM: Inhibition of peptidases in the control of blood pressure. Essays Biochem 2002;38:129-139.
8. Maniu CV, Meyer DM, Redfield MM: Hemodynamic and humoral effects of vasopeptidase inhibition in canine hypertension. Hypertension 2002;40:528-534.
9. Abassi ZA, Yahia A, Zeid S, et al: Cardiac and renal effects of omapatrilat, a vasopeptidase inhibitor, in rats with experimental congestive heart failure. Am J Physiol 2005;288:H722-H728.
10. Cao Z, Burrell LM, Tikkanen I, Bonnet F, Cooper ME, Gilbert RE: Vasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized rats. Kidney Int 2001;60:715-721.
11. Wenzel UO, Wolf G, Jacob I, et al: Beneficial and adverse renal and vascular effects of the vasopeptidase inhibitor omapatrilat in renovascular hypertensive rats. Nephrol Dial Transplant 2003;18:2005-2013.
12. Mifsud SA, Burrell LM, Kubota E, Jaworski K, Cooper ME, Wilkinson-Berka JL: Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats. Clin Exp Hypertens 2004;26:69-80.
13. Nath KA: The tubulointerstitium in progressive renal disease. Kidney Int 1998;54:992-994.
14. Gilbert RE, Cooper ME: The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-1637.
15. Eddy AA: Molecular basis of renal fibrosis. Pediatr Nephrol 2000;15:290-301.
16. Maric C, Aldred GP, Antoine AM, et al: Effects of angiotensin II on cultured rat renomedullary interstitial cells are mediated by AT1A receptors. Am J Physiol 1996;271:F1020-1028.
17. Park SH, Woo CH, Kim JH, et al: High glucose down-regulates angiotensin II binding via the PKC-MAPK-cPLA2 signal cascade in renal proximal tubule cells. Kidney Int 2002;61:913-925.
18. Ina K, Kitamura H, Tatsukawa S, Takayama T, Fujikura Y, Shimada T: Transformation of interstitial fibroblasts and tubulointerstitial fibrosis in diabetic nephropathy. Med Electron Microsc 2002;35:87-95.
19. Siragy HM, Awad A, Abadir P, Webb R: The angiotensin II type 1 receptor mediates renal interstitial content of tumor necrosis factor-alpha in diabetic rats. Endocrinology 2003;144:2229-2233.
20. Awad AS, Webb RL, Carey RM, Siragy HM: Renal nitric oxide production is decreased in diabetic rats and improved by AT1 receptor blockade. J Hypertens 2004;22:1571-1577.
21. Davis BJ, Johnston CI, Burrell LM, et al: Renoprotective effects of vasopeptidase inhibition in an experimental model of diabetic nephropathy. Diabetologia 2003;46:961-971.
22. Schafer S, Schmidts HL, Bleich M, Busch AE, Linz W: Nephroprotection in Zucker diabetic fatty rats by vasopeptidase inhibition is partly bradykinin B2 receptor dependent. Br J Pharmacol 2004;143:27-32.
23. Zhuo J, Maric C, Harris PJ, Alcorn D, Mendelsohn FA: Localization and functional properties of angiotensin II AT1 receptors in the kidney: focus on renomedullary interstitial cells. Hypertens Res 1997;20:233-250.
24. Koh GY, Nussenzveig DR, Okolicany J, Price DA, Maack T: Dynamics of atrial natriuretic factor-guanylate cyclase receptors and receptor-ligand complexes in cultured glomerular mesangial and renomedullary interstitial cells. J Biol Chem 1992;267:11987-11994.
25. Maric C, Aldred GP, Harris PJ, Alcorn D: Angiotensin II inhibits growth of cultured embryonic renomedullary interstitial cells through the AT2 receptor. Kidney Int 1998;53:92-99.
26. Wu Z, Maric C, Roesch DM, Zheng W, Verbalis JG, Sandberg K: Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. Endocrinology 2003;144:3251-3261.
27. Maric C, Sandberg K, Hinojosa-Laborde C: Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol 2004;15:1546-1556.
28. Yamate J, Sato K, Ide M, et al: Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol 2002;39:322-333.
29. Schulte EA, Saleh H, Schlatter E: Diadenosine polyphosphates and atrial natriuretic peptide are antiproliferative in rat mesangial cells. Cell Physiol Biochem 2000;10:57-64.
30. Pandey KN, Nguyen HT, Li M, Boyle JW: Natriuretic peptide receptor-A negatively regulates mitogen-activated protein kinase and proliferation of mesangial cells: role of cGMP-dependent protein kinase. Biochem Biophys Res Commun 2000;271:374-379.
31. Walther T, Stepan H, Pankow K, et al: Relation of ANP and BNP to their N-terminal fragments in fetal circulation: evidence for enhanced neutral endopeptidase activity and resistance of BNP to neutral endopeptidase in the fetus. Bjog 2004;111:452-455.
32. Walther T, Stepan H, Pankow K, Becker M, Schultheiss HP, Siems WE: Biochemical analysis of neutral endopeptidase activity reveals independent catabolism of atrial and brain natriuretic peptide. Biol Chem 2004;385:179-184.
33. Thallas-Bonke V, Lindschau C, Rizkalla B, et al: Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004;53:2921-2930.
34. Mankhey RW, Bhatti F, Maric C: 17beta-Estradiol replacement improves renal function and pathology associated with diabetic nephropathy. Am J Physiol 2005;288:F399-F405.